Merck and Schering-Plough to Merge in $41B Deal

Monday, Mar 9, 2009  |  Updated 6:15 AM CDT
View Comments (
)
|
Email
|
Print
Merck and Schering-Plough to Merge in $41B Deal

AP

Drugmakers Merck & Co. and Schering-Plough Corp. are joining together in a reverse merger.

Drugmakers Merck & Co. and Schering-Plough Corp., already partners in a joint venture, are planning to merge under the name Merck in a stock-and-cash deal worth about $41.1 billion.

Schering-Plough's shareholders will get $10.50 in cash and just over half of one Merck share for each Schering-Plough share they own. That's a 34 percent premium to Schering-Plough's closing stock price on Friday.

The two New Jersey pharmaceutical companies say that Merck's top executive, Chairman and CEO Richard Clarke, will lead the combined company.

However, the transaction and it is to be structured as a reverse merger. As a result Schering-Plough will be the surviving public corporation but will be renamed Merck.

Get the latest headlines sent to your inbox!
View Comments (
)
|
Email
|
Print
Leave Comments
Follow Us
Sign up to receive news and updates that matter to you.
Send Us Your Story Tips
Check Out